首页 › 基金 › Connective Capital Management, LLC › LCTX

Connective Capital Management, LLC 对 LCTX 的持仓历史

LINEAGE CELL THERAPEUTICS IN · 医疗保健

Connective Capital Management, LLC 在 Q3 2026 的 13F 申报中披露持有 LCTX(LINEAGE CELL THERAPEUTICS IN)293,624 股,市值约 US$281K,约占其申报组合的 0.21%,在其申报持仓中市值排名第 47 位。 Connective Capital Management, LLC 于 Q3 2026 首次申报该持仓。

最新持仓 (Q3 2026)293.62K 股
申报持仓市值$280.62K
组合权重0.21%
首次申报Q3 2026
最近变动新进
更新于2026-11-16

最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR

Connective Capital Management, LLC 对 LCTX 的持仓演变

Connective Capital Management, LLC 于 Q3 2026 首次披露 LCTX 持仓:293,624 股(约 US$281K)。

逐季持仓明细

季度股数金额变化
Q3 2026 293.62K $280.62K 新进

关于 LCTX 与 13F 数据

LCTX(LINEAGE CELL THERAPEUTICS IN)属于医疗保健行业。我们追踪的基金中还有 28 只申报持有 LCTX,申报仓位最大的包括:BROADWOOD CAPITAL INC (US$47.4M), Defender Capital, LLC. (US$6.4M), RAFFLES ASSOCIATES LP (US$5.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 LCTX 的基金

查看 LCTX 的全部基金持有人 →

常见问题

How long has Connective Capital Management, LLC held LCTX?

Connective Capital Management, LLC has disclosed LCTX holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is Connective Capital Management, LLC's current position in LCTX?

As of Q3 2026, Connective Capital Management, LLC holds 293.62K shares of LCTX (LINEAGE CELL THERAPEUTICS IN), valued at $280.62K, representing 0.21% of its reported portfolio and ranking #47.

Has Connective Capital Management, LLC been buying or selling LCTX?

In the latest 13F filing (Q3 2026), Connective Capital Management, LLC newly opened its position in LCTX.

Which other funds hold LCTX?

Other major institutional holders of LCTX include BROADWOOD CAPITAL INC, Defender Capital, LLC., RAFFLES ASSOCIATES LP, among 28 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.